ARGX vs MRNA
Argenx SE and Moderna, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ARGX | MRNA |
|---|---|---|
| Revenue | $4.2B | $1.9B |
| Net income | $1.3B | $-2.8B |
| Gross margin | 89.1% | 55.3% |
| Net margin | 31.1% | −145.2% |
| Return on equity | 20.2% | −28.9% |
| Diluted EPS | $19.57 | −$7.26 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $679.0M | $-2.1B |
| Equity | · | $8.7B |
| Net debt / equity | · | −0.23× |
| Current ratio | 5.23× | 3.29× |
| Revenue CAGR 5y | 151.5% | 19.3% |
| Profit CAGR 5y | · | · |
ARGX bills 2.1× the revenue of MRNA, and MRNA closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ARGX | MRNA |
|---|---|---|
| FY2025 | $4.2B | $1.9B |
| FY2024 | $2.2B | $3.2B |
| FY2023 | $1.2B | $6.8B |
| FY2022 | $400.7M | $19.3B |
| FY2021 | $497.3M | $18.5B |
| FY2020 | $41.2M | $803.0M |
| FY2019 | $78.5M | $60.0M |
| FY2018 | · | $135.1M |
| FY2017 | · | $205.8M |
| FY2016 | · | $108.4M |
Bottom line
| Fiscal year | ARGX | MRNA |
|---|---|---|
| FY2025 | $1.3B | $-2.8B |
| FY2024 | $833.0M | $-3.6B |
| FY2023 | $-295.1M | $-4.7B |
| FY2022 | $-709.6M | $8.4B |
| FY2021 | $-408.3M | $12.2B |
| FY2020 | $-608.5M | $-747.0M |
| FY2019 | $-181.2M | $-514.0M |
| FY2018 | · | $-384.7M |
| FY2017 | · | $-255.9M |
| FY2016 | · | $-216.2M |
7 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$2,207,316,000 | ARGX |
| FY2024 | −$1,050,117,000 | MRNA |
| FY2023 | −$5,657,217,000 | MRNA |
| FY2022 | −$18,862,280,000 | MRNA |
| FY2021 | −$17,973,723,000 | MRNA |
| FY2020 | −$761,757,000 | MRNA |
| FY2019 | +$18,462,000 | ARGX |
The higher-revenue side has changed between ARGX and MRNA over this period. The gap has widened since the earliest year compared.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
8 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +176.3 pp | ARGX |
| FY2024 | +148.2 pp | ARGX |
| FY2023 | +44.1 pp | ARGX |
| FY2022 | −220.5 pp | MRNA |
| FY2019 | +625.7 pp | ARGX |
| FY2018 | −25.4 pp | MRNA |
| FY2017 | +47.2 pp | ARGX |
| FY2016 | +54.2 pp | ARGX |
The higher net margin has changed hands between ARGX and MRNA over this period.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's net margin has been more volatile than ARGX's over the 8 comparable fiscal years — 257.2 percentage points of standard deviation against 117.6.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ARGX and MRNA over these 8 fiscal years — ARGX led in 6 and MRNA in 2.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRNA's return on equity has been more volatile than ARGX's over the 7 comparable fiscal years — 64.6 percentage points of standard deviation against 21.3.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ARGX and MRNA over these 7 fiscal years — ARGX led in 4 and MRNA in 3.
7 of 11 comparable fiscal years — a year missing data on either side is not counted.